Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Levothyroxine, which is the third most popular drug in the US and the main drug used to treat primary hypothyroidism, also possesses clinically significant interactions with food, beverages, and supplements that can change the safety and efficacy of thyroid-hormone replacement therapies. This review article from Pharmaceuticals reviews 925 hypothyroid patients that highlighted “disturbing” lifestyle and diet patterns.
Endocrinology, Diabetes, Metabolism June 23rd 2022
Although many studies have claimed that moderate alcohol consumption and drinks such as red wine can be healthy for the human heart, a new study presented at the European Society of Cardiology 2022 meeting takes a contrarian viewpoint and draws a link between alcohol consumption and heart failure in people with hypertension, diabetes, or obesity.
Cardiology May 31st 2022
Annals of Internal Medicine
A new study published in Annals of Internal Medicine looks at the link between cardiovascular disease among adults with type 2 diabetes, which might be more prevalent than previously thought. This study compares cardiovascular outcomes in patients taking first line metformin vs. SGLT-2 inhibitors, based on claims data over a 7-year period. SGLT-2 inhibitor use was associated with lower rates of hospitalization for heart failure and all cause mortality. Rates for MI and stroke were similar for the two treatments.
Monthly Prescribing Reference (MPR)
Mounjaro (tirzepatide) is a first-in-class, once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single molecule. It enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. The FDA approval of Mounjaro as an adjunct therapy to diet and exercise for adults with type 2 diabetes was based on clinical trials where treatment with Mounjaro resulted in statistically significant reduction in both A1c and weight vs. semaglutide, insulin degludec, and insulin glargine.
Endocrinology, Diabetes, Metabolism May 24th 2022
Lilly Pharmaceutical’s Mounjaro (tirzepatide) is a once-weekly injection that promotes weight loss by mimicking the effects of incretins. This combination of a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) yields weigh loss results comparable to surgical options.
Endocrinology, Diabetes, Metabolism May 17th 2022
Among adults aged 35 years or older with a body mass index (BMI) of 25 kg/m2, the prevalence of diabetes in Asian, Black, and Hispanic Americans was significantly higher than that in White Americans. Using screening thresholds specific to race and ethnicity has the potential to reduce disparities in diabetes diagnosis.